Dupilumab for treating eosinophilic oesophagitis in people aged 12 years and older

Dupilumab is in clinical development for the treatment of eosinophilic oesophagitis (EoE) in adults
and adolescents. EoE is a condition that affects the gullet (oesophagus). There is a build-up of a
particular type of immune cell (eosinophils) in the lining of the gullet causing inflammation or
irritation. This affects how the gullet works, causing symptoms such as difficulty swallowing. EoE
has been identified only since the early 1990s but is now considered a major cause of digestive
system (gastrointestinal) illness. Research is ongoing and will likely lead to revisions in the
diagnosis and treatment of EoE, as there is currently an unmet need for appropriate treatment
options.